People · Operator
Named in public records as an officer, director or promoter · active 2010–2017 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bi02 Medical, Inc. | — | Biotechnology | Series A | $35.6M | $54.2M | 2010 |
| Bluegrass Vascular Technologies, Inc. | — | Other | Series A | $4.8M | $72.6M | 2014 |
Alan Dean at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alan Dean on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Castella | 1 | 6 |
| John Creecy | 1 | 5 |
| James Clifton | 1 | 3 |
| Steven Bailey | 1 | 2 |
| John Elwood | 1 | 2 |
| Robert Coleman | 1 | 2 |
| Christopher Banas | 1 | 2 |
| Luis Angel | 1 | 1 |
| James Traa | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.